Drugs /

glumetinib

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, glumetinib targets and binds to the c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

Clinical Trials

View Clinical Trials for glumetinib

Glumetinib has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating glumetinib, 1 is phase 1/phase 2 (1 open).

EGFR A763_Y764insFQEA, EGFR Codon 719 Missense, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for glumetinib clinical trials.

Non-small cell lung carcinoma is the most common disease being investigated in glumetinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Glumetinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating glumetinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
glumetinib, glumetinib, scc 244, scc244, scc-244
Drug Target(s) [2]:
MET
NCIT ID [1]:
C156700

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.